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ABSTRACT
Introduction: Premix insulin analogs are a
well-established treatment for type 2 diabetes
(T2D). However, there is a lack of simple, clear
guidance on some aspects of their use. These
include choosing a regimen for insulin
initiation, recognizing when patients need
intensification of therapy, and switching from
basal–bolus to a premix insulin analog when
appropriate.
Methods: An independent expert panel
formulated recommendations on the use in
T2D of the premix insulin analog formulations
widely available in Australasia, based on the
available evidence and their own experience.
Results: Results from trials in both initiation
and intensification of insulin show that no
single insulin or regimen is best on all
endpoints, and that improved glycemic
control can be expected regardless of which
regimen is used. Thus, individual patient factors
and preferences become more important.
Guidance is presented to help the clinician
choose between a premix insulin analog or
basal analog for insulin initiation, and to
intensify insulin therapy using premix insulin
analogs. Recommendations are made on
dosing, titration, the concomitant use of non-
insulin glucose-lowering drugs, and other
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practical issues, and on the special case of
switching from basal–bolus to premix insulin
analog therapy.
Conclusion: This guidance is intended to help
both general and specialist practitioners make
informed choices and provide optimal care for
patients with T2D. It emphasizes the
importance of taking into account individual
patient factors and preferences so that the
choice of insulin regimen is individualized to
the patient in the same way that glycemic
targets are now individualized.
Funding: Novo Nordisk Region IO A/S.
Keywords: Basal insulin; Biphasic insulin
aspart; Biphasic insulin lispro; Insulin
initiation; Insulin intensification; Premix
insulin analogs
INTRODUCTION
Premix insulin analogs are well established as a
treatment for type 2 diabetes (T2D). However,
there is a lack of clear practical guidance to help
clinicians choose an initial regimen. A number
of overarching criteria need to be taken into
consideration. These include the need to target
both fasting plasma glucose (FPG) and
postprandial glucose (PPG) to achieve optimal
glycemic control [1]; the importance of
individualizing therapy; and the need to
intensify the insulin regimen to compensate
for the progressive nature of diabetes.
Furthermore, currently available literature
contains almost no information on how to
switch patients from basal–bolus to premix
therapy when patients fail to cope with the
more intensive insulin regimen. With the
growing prevalence of T2D, the responsibility
for the care of patients is increasingly moving to
general practitioners (GPs), many of whom
would welcome clear and straightforward
guidance on insulin management.
With this in mind, the authors of this
report—an independent expert panel of
endocrinologists and GPs with a special
interest in diabetes, all based in Australia and
New Zealand—met in Sydney in February 2014.
The panel’s objective was to formulate guidance
on how to undertake the following activities:
initiating therapy with premix insulin analogs;
recognizing when patients need intensification
of their insulin therapy; and switching from
basal–bolus to premix insulin analog therapy
when appropriate.
METHODS
The panel chose to focus on the premix insulin
analog formulations widely available in
Australasia as of February 2014: biphasic
insulin aspart, containing 30% soluble insulin
aspart and 70% protamine-crystallized insulin
aspart (BIAsp 30), and biphasic insulin lispro,
containing 25% soluble insulin lispro and 75%
protamine-crystallized insulin lispro (lispro
mix 25). In this document, the term ‘premix
insulin analogs’ covers both BIAsp 30 and lispro
mix 25; the term ‘premix insulins’ is used to
cover both human and analog premixes when
citing references where the term was used in
this way.
The panel’s intention is that the guidance
should be specific and detailed enough to be
useful in primary care as well as for specialists. As
far as possible, the recommendations are
evidence based. However, since the evidence
on approaches for treatment is incomplete, some
of the recommendations are given by the writing
group as a consensus and indicated as such.
The guidance in this statement covers T2D
only and does not include type 1 diabetes,
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gestational diabetes, latent autoimmune
diabetes of adults, patients in end-stage renal
disease, or steroid-induced diabetes. The
recommendations have been formulated for
Australia and New Zealand, but should be
useful globally. No representations are made
about local prescribing regulations or funding
status in specific countries. Currently, evidence
is not available to make recommendations
concerning new combination insulins, such as
insulin degludec/insulin aspart, or other new
combination regimens such as insulin–incretin
combinations. This guidance will, therefore, be
subject to change as new information becomes
available.
It should be noted that the guidance
provides recommendations that are intended
to be helpful, and that none of the suggested
actions are mandatory.
This article is based on previously conducted
studies and does not involve any new studies of




Previously, guidelines on the management of
T2D prescribed fixed glycemic targets for all
patients. More recent guidance from bodies
such as the American Diabetes Association
(ADA), the European Association for the
Study of Diabetes (EASD), and the
International Diabetes Federation (IDF) have
formalized the concept of ‘patient-centered
care’, which includes setting targets in line
with individual patients’ needs, preferences,
and tolerances [2, 3]. This concept is now
increasingly accepted. Glycemic targets that
will be appropriate for most patients are still
suggested, as shown in Table 1, but with the
understanding that individualization of targets
is imperative.
Choosing an appropriate insulin type and
regimen should also be based on specific patient
attributes [5], rather than taking a ‘one-size-fits-
all’ approach, and many guidelines now
recognize both basal and premix insulin as
options for initiating/intensifying insulin
therapy in T2D (Table 1). Indeed, the loss of
the first-phase insulin release is one of the
earliest detectable defects of beta-cell function
in individuals destined to develop T2D [9]. The
resultant postprandial hyperglycemia has been
associated with an increased risk of harmful
outcomes such as macrovascular disease,
retinopathy, and cancer [1]. Unlike basal
insulin, premix insulin targets both FPG and
PPG, which is essential for addressing this
glycemic defect and achieving optimal
glycemic control. With this in mind, it is
important to determine the glycemic defect
through blood glucose monitoring before
choosing an insulin initiation regimen.
It is important to note that the ADA/EASD
statement emphasizes the progressive nature of
T2D and the likelihood that intensification of
therapy will be needed as beta-cell function
deteriorates [2].
Evidence Base for Premix Insulin Analogs
in Initiation, Intensification,
and Switching
Initiation of Insulin: Premix Insulin Analogs
Vs. Basal Analogs
An extensive clinical dataset, based on
numerous randomized clinical trials and real-
life observational studies, supports the efficacy
and good safety profiles of BIAsp 30 and lispro
mix 25 in the initiation and intensification of
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insulin therapy; these data have been reviewed
[10, 11].
A small number of trials compared the use of
either premix insulin analogs or basal insulin
analogs for insulin initiation. Systematic
reviews of the available evidence [12–14]
suggest that treatment with premix insulin
analogs as first-line insulin therapy results in
significantly better overall glycemic control, but
slightly greater risk of hypoglycemia and weight
gain, compared with basal insulin. A more
recent review of eight trials comparing insulin
initiation with either premix analogs or basal
analogs showed greater glycated hemoglobin
(HbA1c) reductions, weight gain, and number
of hypoglycemic episodes with the premix
analogs (significance of differences not
reported) [15]. The authors suggested that
factors that are not addressed in clinical trials,
such as complexity of regimens and the need for
titration, may influence outcomes.
The most recently published trial comparing
BIAsp 30 once daily (OD) with a basal analog
(insulin glargine OD) for insulin initiation in
T2D was OnceMix (ClinicalTrials.gov number,
NCT00469092) [16]. The estimated mean
reduction in HbA1c was -1.41%
(15 mmol/mol) with BIAsp 30 and -1.25%
(14 mmol/mol) with insulin glargine
(difference [95% confidence interval]: -0.16%
[-0.30; -0.02] or -2 mmol/mol [-3; -0.2];
P = 0.029). There was a significant
improvement in PPG with BIAsp 30 after
dinner and before bed when compared with
insulin glargine, with differences of
-0.52 mmol/L (P = 0.04) and -0.78 mmol/L
(P\0.01), respectively. The risk of
hypoglycemia, while low in both groups, was
slightly higher with BIAsp 30 for overall
hypoglycemia (6.5 vs. 4.8 episodes/patient-
year; P = 0.034) and nocturnal hypoglycemia
(1.1 vs. 0.5 episodes/patient-year; P = 0.003).
However, the proportion of patients who
achieved an HbA1c level \7% with no
hypoglycemia was the same in the two groups
(20.0% with BIAsp 30 and 19.4% with insulin
glargine). Weight change did not differ between
the groups.
DURABLE (ClinicalTrials.gov number,
NCT00279201) compared lispro mix 25 twice
daily (BID) with insulin glargine OD in
previously insulin-naı¨ve patients [17].
Treatment with lispro mix 25 resulted in
slightly greater reductions in HbA1c at
24 weeks: -1.8 ± 1.3% (-20 ± 14 mmol/mol)
vs. -1.7 ± 1.3% (-19 ± 14 mmol/mol)
(P = 0.005). The lispro mix group also had
more weight gain: 3.6 ± 4.0 vs. 2.5 ± 4.0 kg
(P\0.0001) and higher rates of overall
hypoglycemia (28.0 ± 41.6 vs. 23.1 ± 40.7
episodes/patient-year; P = 0.007), but lower
rates of nocturnal hypoglycemia (8.9 ± 19.3 vs.
11.4 ± 25.3 episodes/patient-year; P = 0.009). A
follow-up study over 24 months showed
durability of glycemic control was longer with
lispro mix 25 [18].
Intensification of Insulin: Premix Insulin
Analogs vs. Basal-Plus or Basal–Bolus
Regimens
A meta-analysis published in 2011 [19]
compared premix insulin analogs with basal–
bolus therapy based on three trials: PREFER
(ClinicalTrials.gov number, NCT00605020),
which compared BIAsp 30 BID with insulin
detemir plus insulin aspart at mealtimes [20]; a
study comparing lispro mix 50 (containing 50%
soluble insulin lispro and 50% protamine-
crystallized insulin lispro) three times daily
(TID) with insulin glargine plus insulin lispro
TID [21]; and the 3-year follow-up of the 4T
study, comparing BIAsp 30 BID, insulin aspart
TID, or insulin detemir OD or BID as initial
regimens [22]. In 4T, if glycemic control was
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inadequate, lunchtime insulin aspart was added
to BIAsp 30 BID, bedtime basal insulin was
added to insulin aspart TID, and insulin aspart
TID was added to basal insulin. Most of the
patients in the prandial and basal groups
switched to basal–bolus therapy [23]. Based on
these three trials, the authors concluded that
patients treated with a basal–bolus regimen had
a higher chance of reaching their HbA1c goal
(odds ratio [95% confidence interval]: 1.75
[1.11; 2.77]), with no difference in incidence
of hypoglycemia or weight gain between the
two regimens [19]. The results have to be
interpreted cautiously, as the trial populations
included insulin-naı¨ve patients as well as
patients already receiving basal insulin at the
start of the treatment periods.
Further studies have been published since
2011, some only as abstracts at the time of the
panel meeting. In PARADIGM
(ClinicalTrials.gov number, NCT00548808),
lispro mix 25 OD, BID, or TID, as needed, was
compared with insulin glargine plus one, two,
or three injections of insulin lispro, as needed.
Glycemic control, weight change,
hypoglycemia, the number of injections, and
the increase in insulin dose were all similar
between groups [24]. A phase IV study,
GALAPAGOS (ClinicalTrials.gov number,
NCT01121835), compared BIAsp 30 OD or BID
with insulin glargine OD plus insulin glulisine
OD if needed (‘basal-plus’). With BIAsp 30,
52.6% of patients achieved HbA1c \7%
compared with 43.2% of those receiving basal-
plus (P = 0.005). However, rates of
hypoglycemia were higher with BIAsp 30: 2.9
vs. 1.2 episodes/patient-year for overall
hypoglycemia, and 1.0 vs. 0.4
episodes/patient-year for nocturnal episodes
(both P\0.01) [25]. Finally, the LanScape
study (ClinicalTrials.gov number,
NCT00965549) compared BIAsp 30 OD with
insulin glargine OD plus insulin glulisine OD
at the main meal [26]. Reduction in HbA1c did
not differ between the two regimens. There was
no difference between overall hypoglycemia
rates, but there were fewer nocturnal events
with BIAsp 30 OD (3.6 vs. 5.7 events/patient-
year; P = 0.02).
Factors influencing the choice of either
premix insulin analogs or basal–bolus regimens
for intensification in a primary care setting have
recently been reviewed [27]. The authors of this
study found inconclusive evidence and a lack of
direct comparisons, and pointed out that
clinical trials do not necessarily reflect real-
world patients. In their view, GPs know their
patients well and are in a good position to select
the appropriate regimen for their patients (e.g.,
premix or basal-plus/basal–bolus therapy).
However, GPs need sufficient time and support
to accomplish this task.
Switching from Basal–Bolus to Premix Therapy
Switching from a basal–bolus insulin regimen to
premix insulin analogs is a relatively
uncommon scenario. While basal–bolus
therapy is considered the ‘gold standard’ for
patients with advanced T2D, two groups of
patients may need to switch to premix insulin
analogs either BID or TID. These are patients
who are unable or unwilling to cope with the
complexity of a basal–bolus regimen, and
patients who commence treatment with basal–
bolus therapy in hospital (as occurs routinely in
Australia, in accordance with guidelines from
the Australian Diabetes Society [28]) and no
longer require such an intensive regimen
following discharge.
There is minimal published evidence on how
to make this switch. Some evidence is available
from a subgroup of the observational A1chieve
study (ClinicalTrials.gov number, NCT00869
908), in which patients who were inadequately
278 Diabetes Ther (2015) 6:273–287
controlled on antidiabetic medication started or
were switched to either BIAsp 30, insulin aspart,
or insulin detemir [29]. The subgroup consisted
of patients who were inadequately controlled
on basal–bolus therapy using insulin glargine
(n = 240) or neutral protamine Hagedorn
insulin (n = 784) and who switched to
BIAsp 30, mostly BID [30]. At 24 weeks, mean
HbA1c decreased by approximately 2.5%
(27 mmol/mol) and 1.9% (21 mmol/mol),
respectively (P\0.001 in both groups). The
proportions reporting overall, major, or
nocturnal hypoglycemia were significantly
reduced (P\0.05 in all cohorts) after
switching to BIAsp 30. While this was not a
randomized trial, the results do suggest that
selected patients inadequately controlled on a
basal–bolus regimen can benefit by switching to
a premix insulin analog. The authors speculate
that the improved results may have arisen from
better therapy adherence due to the simpler
regimen with BIAsp 30.
To our knowledge, the only previously
published recommendations for switching
from basal–bolus therapy to premix insulin
analogs were included in Turkish guidelines,
not available in English, on the use of BIAsp 30
in T2D [31]. These suggested that patients
should be switched to BIAsp 30 BID or TID in
preference to OD.
Conclusions from the Available Evidence
The results from the trials in both initiation and
intensification of insulin show that, in general,
a better HbA1c reduction was accompanied by a
higher rate of hypoglycemia, and both arms
were accompanied by weight gain. No single
insulin or regimen was best on all endpoints.
Furthermore, while the differences may have
reached statistical significance, they were often
of limited clinical relevance. It is clear that
improved glycemic control can be expected,
irrespective of which regimen is used. Thus,
individual patient factors and preferences
become more important, and the focus must
be on selecting the regimen that is best for the
particular patient—including any features likely
to aid adherence.
It is important to choose a regimen to which
patients are likely to adhere. Non-adherence to
insulin therapy has been linked with
unfavorable outcomes [32, 33]; conversely,
treatment persistence has been associated with
improved clinical outcomes [34]. A full
discussion of adherence issues is outside the
scope of this guidance. However, studies of
adherence to antidiabetic therapy in general
(not necessarily insulin) have shown that
factors affecting adherence include the
patient’s comprehension of the treatment
regimen and its benefits, adverse effects,
medication costs, regimen complexity, and
frequency and timing of dosing [35, 36]. One
study showed that the main predictor of
adherence was patients’ ratings of the burden
of therapy, and that the patients’ perceived
burden of therapy increased as the number of
injections increased [37].
Very little evidence is available on the
scenario in which patients need to switch
from basal–bolus to premix insulin therapy.
RECOMMENDATIONS
Initiating Insulin Therapy with Premix
Insulin Analogs in Primary Care
Preparing Patients for Insulin Therapy
Patients may fear initiating insulin for many
reasons: fear of hypoglycemia or weight gain;
concern that insulin therapy indicates that they
are heading towards severe complications such
as blindness, limb amputation, or kidney
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failure; resistance to the need for monitoring
blood glucose; or a belief that starting insulin
indicates a failure on their part. It is important
to allay these fears [38, 39]. It is also important
to select the right HbA1c target for the
individual patients. If the target is set too low,
patients may omit insulin to avoid
hypoglycemia, at the expense of their
glycemic control.
Choosing the Most Appropriate Insulin
Regimen for the Patient
When choosing an insulin regimen for
initiation, it is imperative to bear in mind the
long-term progressive nature of T2D and the
likely need for intensification. The patient’s
ability to cope with intensification should
influence the choice of initiation regimen.
Figure 1 summarizes patient characteristics
that may help determine a preference for either
basal insulin or premix insulin analogs. Choose
the regimen that provides the best match
overall to the characteristics described. Age is
not shown in Fig. 1, as function and degree of
frailty are more important than chronological
age. If life expectancy is short, the probability of
future insulin intensification is less important.
Dosing, Titration, and Monitoring
See ‘‘Box 1’’ for guidance on dose and titration
when initiating insulin with premix insulin
analogs.
Fig. 1 Patient factors to consider when deciding whether
to use premix insulin analog or basal insulin for initiation
(based on consensus). The ﬁgure shows both immediately
applicable factors and other factors that will determine
whether future intensiﬁcation should be with basal–bolus
or premix insulin analog therapy
280 Diabetes Ther (2015) 6:273–287
When titrating, use the lowest of the three
most recent self-monitored blood glucose
(SMBG) values (premeal, at least 8 h after
last injection) to decide whether to adjust
the dose. If the dose reaches 40–50 units,
consider splitting it by adding another
injection.
Schedule regular clinical review. Review
therapy if SMBG is not near target despite
increasing dose of insulin ([1 unit/kg per day).
Factors to review include patient’s diet,
compliance with insulin, injection technique,
and injection sites.
Use of Other Glucose-Lowering Drugs
See ‘‘Box 2’’ for guidance on the use of other
glucose-lowering drugs when initiating insulin
with premix insulin analogs.
Box 2: Use of other glucose-lowering drugs
(based on consensus)
• All combination use is subject to local
registration rules.
• Metformin should always be continued
unless it is poorly tolerated or
contraindicated (e.g., patient with renal
dysfunction).
• Consider maintaining sulfonylureas with
once-daily premix insulin. However, they
should not be given at the same time of
day as the premix insulin dose.
Discontinue sulfonylureas once patients
intensify to twice-daily premix insulin.
• Dipeptidyl peptidase-4 inhibitors/sodium-
glucose cotransporter-2 inhibitors/alpha-
glucosidase inhibitors can be continued
together with insulin.
• Thiazolidinediones: combining these
agents with insulin may exacerbate
edema.
• Glucagon-like peptide-1 agonists may be
insulin sparing and can be used.
• Consider lowering the dose of the non-
insulin drug, other than metformin, at
insulin initiation.
1 If HbA1c is above a certain point [we suggest C8.5%
(C70 mmol/mol)], it is also possible to initiate therapy
with 6 units BID.
Box 1: Dosing/titration guidelines for
initiating insulin with premix insulin
analogs OD (based on consensus)
• When choosing an insulin dose, and for
dose titration, err on the side of safety and
convenience.
• Initiate with premix insulin analog OD,
immediately before or soon after the start
of the meal with the highest prandial load
(usually the evening meal).
• Initiate with a dose of 10–12 units and
titrate.1
• Increase by 2 units once or twice a week
until the patient reaches target [aim for
\7 mmol/L (\126 mg/dL), but no
values\4 mmol/L (\72 mg/dL) based on
the lowest premeal glucose level] or
experiences hypoglycemia (see dose
adjustment table). Dose titration can be
halted when self-monitored blood glucose
levels consistently fall within the target.
• If blood glucose\4 mmol/L (\72 mg/dL)
or hypoglycemia occurs, down-titrate by
2 units. If hypoglycemia persists, the







C7.0 mmol/L (C126 mg/dL) ?2 units
4.1–6.9 mmol/L (73–124 mg/dL) 0 units
B4.0 mmol/L (B72 mg/dL) -2 units
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Intensifying Insulin Therapy to Premix
Insulin Analogs BID in Primary Care
This guidance covers intensification from
premix insulin analogs OD or basal insulin
only to premix insulin analogs BID. Other
choices of intensification regimen are not
covered here. For a review of the options for a
second-line insulin regimen, see Barnett and
colleagues [40].
When to Intensify
Intensification of insulin therapy is as
important as initiation. Regular review with
appropriate dose adjustment is critical, to
ensure that the patient does not continue
on their initiation regimen if glycemic
control is suboptimal. Intensification is
required if the individual’s HbA1c level
remains above the individualized target for
3–6 months without any obvious reversible
reason such as a steroid course or dietary
non-compliance. Insulin should also be
intensified if 2-h postprandial blood
glucose values are above 10 mmol/L
(180 mg/dL) and there is a difference
(postmeal minus premeal) of C3 mmol/L
(C54 mg/dL), or when the maximum dose
of 40–50 units is reached on premix insulin
analog OD.
Practical Guidance for Switching
Practical guidance already exists for intensifying
from basal insulin only or premix insulin
analog OD to premix insulin analog BID [41].
‘‘Box 3’’ and Figs. 2 and 3 have been adapted
from this reference. For titration and
monitoring when intensifying to premix
insulin analog BID, refer to the guidance
above on initiation (‘‘Box 1’’).
As mentioned in ‘‘Box 3’’, the total dose will
usually be split 50/50 pre-breakfast and pre-
dinner. However, this pattern may need to be
varied in patients who eat light breakfasts or a
main meal at lunch [42].
If sulfonylureas have not already been
discontinued, stop them when intensifying to a
premix insulin analog BID. Also, take into
consideration patient preference with respect to
Fig. 2 A simple algorithm for switching from basal insulin
therapy OD or BID (analog or human) to BID premix
insulin analog. Modiﬁed from [41]. BID twice daily, FPG
fasting plasma glucose, OD once daily
Box 3: Practical guidance for switching from
basal insulin [once daily (OD) or twice daily
(BID)], or from premix insulin analog OD, to
premix insulin analog BID (based on
consensus). Modified from [41].
• From basal: 1:1 total dose switch to
premix insulin analog. Split the dose
50/50 breakfast and dinner.
• From premix insulin analog OD: split the
OD dose 50/50 breakfast and dinner.
• Administer premix insulin analog
immediately before or soon after the
start of a meal.
• Titrate the dose preferably once or twice a
week (see ‘‘Box 1’’).
• Adjust the evening meal dose first,
followed by the breakfast dose.
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factors such as cost and pill loadwhendeciding to
cease other non-insulin glucose-lowering drugs.
If the patient is switching from an analog
basal-only regimen, remember to educate them
on the need to resuspend the protaminated
insulin and the need to administer insulin with
a meal.
Further Intensification for Patients Already
on Premix Insulin Analog BID
Use of premix insulin analogs TID may be
needed owing to poor control, but this
regimen is used much less often than premix
insulin analogs OD or BID. In the panel
members’ experience, the move from two to
three injections daily can represent a larger
barrier to patients than the move from one to
two injections; patients must also be willing to
undertake sufficient self-testing. If control is not
satisfactory using a premix insulin analog BID,
consider referring the patient to a specialist;
otherwise, refer to the existing practical
guidance for intensification [41].
The ratio of short- to intermediate-acting
insulin in both BIAsp 30 and lispro mix 25 will
be appropriate for most patients. Different ratio
premixes, such as 50% soluble rapid-acting
insulin/50% protaminated insulin, are also
available and can be useful for patients with
specific needs (e.g., patients with very high PPG
values or problems with hypoglycemia). For
information on intensifying to higher ratio
premix insulin analogs, refer to the published
guidance [43].
Switching from Basal–Bolus to Premix
Insulin Analog Therapy in Primary Care
Practical Guidance: Chronic Treatment
Failure
Not all patients achieve successful glycemic
control with long-term basal–bolus therapy.
The reasons for this are many and, with
further education, the regimen may prove to
be appropriate. For others, switching to a
premix insulin analog may be the right
decision. For example, some patients are
unwilling or unable to deal with complexity,
or they may have tried a basal–bolus regimen
but their circumstances may have changed.
Others may find carbohydrate counting, dose
adjustment, or the required degree of
monitoring too difficult, or be unable to
handle two different insulin delivery devices.
To date, there is limited published evidence
concerning this change, although all practicing
endocrinologists will have experience in this
situation. Rather than suggesting a specific
HbA1c cutoff for switching regimens, we
suggest a switch to premix insulin analogs in
patients who are clearly unable or unwilling to
use basal–bolus therapy, or whose HbA1c has
consistently remained above target despite
using a basal–bolus regimen while having
Fig. 3 A simple algorithm for intensifying premix insulin
analog therapy from OD to BID. Modiﬁed from [41].
aThe evening meal is given as an example. Breakfast
injections may also be suitable, in which case the
pre-evening meal blood glucose should be monitored.
bSplit the OD dose 50/50 breakfast and dinner. BID twice
daily, FPG fasting plasma glucose, OD once daily
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access to proper training and adequate
information.
The default switch is to premix insulin
analog BID, not TID, and the titration
guidance shown in ‘‘Box 4’’ is our suggested
approach. If the patient is transferring from an
analog basal–bolus regimen, education
concerning the need to resuspend the
protaminated insulin is important.
Practical Guidance: Patients Discharged
from Hospital
Some hospitalized patients may have been
placed on a basal–bolus regimen to provide a
flexibility of management that is not required
following discharge. Under these
circumstances, switching to an alternate
premix insulin regimen would be appropriate.
In such patients, it is important to be
conservative, and insulin requirements may
change dramatically from those required in
hospital. Discharge planning is vital and
expert input is desirable. For titration
guidelines, see ‘‘Box 4’’.
CONCLUSIONS
The purpose of this document is to provide
practical and simplified guidance on the use of
premix insulin analogs for insulin initiation
and intensification in patients with T2D.
A review of published studies clearly
demonstrates that proper use of any insulin
regimen will result in a reduction in HbA1c, but
that the greater the improvement in glycemic
control, the greater the risk of side effects. Thus,
individual patient factors and preferences
become more important. As such, the choice
of insulin regimen should be individualized to
the patient, in the same way that glycemic
targets are now individualized.
A figure is provided to help clinicians choose
between premix insulin analogs or basal insulin
for insulin initiation (Fig. 1). Key to making this
choice is the need to bear in mind the patient’s
ability to cope with either a premix insulin
analog or basal–bolus regimen when
intensification of therapy is needed.
Guidance is provided on dosing, titration,
the concomitant use of non-insulin glucose-
lowering drugs, and other practical issues in
both initiation and intensification. A titration
algorithm is provided for the special case of
switching from basal–bolus to premix insulin
analog therapy (‘‘Box 4’’). In all situations, safety
is key and insulin should be titrated slowly.
The expert panel hopes that these
recommendations, and in particular the
specific dose values and targets, will prove a
useful resource for all clinicians as they seek to
provide optimal care for their patients with
T2D.
Box 4: Titration algorithm for switching
from basal–bolus to premix insulin analog
(based on consensus)
• General guidance: as always, titration
must be tailored to the individual patient.
• These guidelines do not override clinical
judgment and knowledge.
• Reduce total daily dose of all insulin by
20–30%.
• Then split this value 50/50 to give you the
starting dose of premix insulin analog at
breakfast and evening meal.
• Unusual meal patterns may lead you to
reconsider the initial dose ratio.
• Titrate the dose preferably once or twice a
week (see ‘‘Box 1’’). Adjust the evening
meal dose first, followed by the breakfast
dose.
• Safety is key: go slowly.
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